Online inquiry

IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6732MR)

This product GTTS-WQ6732MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6732MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7254MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FP-1302
GTTS-WQ3860MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BCD-089
GTTS-WQ14242MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ15588MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ9005MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMA-638
GTTS-WQ9468MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ5721MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ582MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 62-71-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW